Abstract
Aspirin has been associated with a reduced risk of colorectal cancer. With specific reference to urological cancers, a protective role for aspirin has been suggested for prostate cancer, but data for cancers of the bladder and kidney have been limited and inconsistent. Epidemiological evidence suggests that prostate cancer risk is reduced by 10% in regular aspirin users, with similar risk reductions reported in both case-control and cohort studies, and for both slow-growing and aggressive cancers. However, risk estimates were significantly heterogeneous and there was no relationship between risk reduction and frequency, dose or duration of use. Thus, inference for causality and public health implications remain far from conclusive. Although a few case-control studies have reported a favorable effect of aspirin on bladder cancer, most investigations did not find any meaningful association. A modest nonsignificant increased risk was reported for kidney cancer. Such excess risk, however, might be due to exposure to phenacetin-containing analgesics, which have been reported to increase renal cell cancer risk.
Key Points
-
Regular aspirin use is associated with a 10% reduced risk of prostate cancer
-
Overall, there is no relationship between frequency, dose or duration of aspirin use and prostate cancer risk
-
Regular aspirin use is unrelated to subsequent bladder cancer risk
-
The apparent excess risk of kidney cancer in relation to aspirin use might be due, at least in part, to misclassified exposure to phenacetin-containing analgesics
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bosetti, C., Gallus, S. & La Vecchia, C. Aspirin and cancer risk: an update to 2001. Eur. J. Cancer Prev. 11, 535–542 (2002).
Bosetti, C., Gallus, S. & La Vecchia, C. Aspirin and cancer risk: an updated quantitative review to 2005. Cancer Causes Control 17, 871–888 (2006).
Cuzick, J. et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol. 10, 501–507 (2009).
Taketo, M. M. Cyclooxygenase-2 inhibitors in tumorigenesis (Part I). J. Natl Cancer Inst. 90, 1529–1536 (1998).
Taketo, M. M. Cyclooxygenase-2 inhibitors in tumorigenesis (Part II). J. Natl Cancer Inst. 90, 1609–1620 (1998).
Elwood, P. C., Gallagher, A. M., Duthie, G. G., Mur, L. A. & Morgan, G. Aspirin, salicylates, and cancer. Lancet 373, 1301–1309 (2009).
Langley, R. E. et al. Aspirin and cancer: has aspirin been overlooked as an adjuvant therapy? Br. J. Cancer 105, 1107–1113 (2011).
Sabichi, A. L. & Lippman, S. M. COX-2 inhibitors and other nonsteroidal anti-inflammatory drugs in genitourinary cancer. Semin. Oncol. 31, 36–44 (2004).
Davidsson, S. et al. Inflammation, focal atrophic lesions, and prostatic intraepithelial neoplasia with respect to risk of lethal prostate cancer. Cancer Epidemiol. Biomarkers Prev. 20, 2280–2287 (2011).
Yoshimura, R. et al. Expression of cyclooxygenase-2 in prostate carcinoma. Cancer 89, 589–596 (2000).
Gupta, S., Srivastava, M., Ahmad, N., Bostwick, D. G. & Mukhtar, H. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 42, 73–78 (2000).
Balkwill, F. & Mantovani, A. Inflammation and cancer: back to Virchow? Lancet 357, 539–545 (2001).
Dennis, L. K., Lynch, C. F. & Torner, J. C. Epidemiologic association between prostatitis and prostate cancer. Urology 60, 78–83 (2002).
Pelucchi, C., Talamini, R., Negri, E., Franceschi, S. & La Vecchia, C. Genital and urinary tract diseases and prostate cancer risk. Eur. J. Cancer Prev. 15, 254–257 (2006).
Shirahama, T. & Sakakura, C. Overexpression of cyclooxygenase-2 in squamous cell carcinoma of the urinary bladder. Clin. Cancer Res. 7, 558–561 (2001).
Shariat. S. F. et al. Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder. J. Urol. 169, 938–942 (2003).
Castelao, J. E., Yuan, J. M., Gago-Dominguez, M., Yu, M. C. & Ross, R. K. Non-steroidal anti-inflammatory drugs and bladder cancer prevention. Br. J. Cancer 82, 1364–1369 (2000).
Fortuny, J. et al. Use of analgesics and nonsteroidal anti-inflammatory drugs, genetic predisposition, and bladder cancer risk in Spain. Cancer Epidemiol. Biomarkers Prev. 15, 1696–1702 (2006).
Fortuny, J. et al. Analgesic and anti-inflammatory drug use and risk of bladder cancer: a population based case control study. BMC Urol. 7, 13 (2007).
McCredie, M., Stewart, J. H., Ford, J. M. & MacLennan, R. A. Phenacetin-containing analgesics and cancer of the bladder or renal pelvis in women. Br. J. Urol. 55, 220–224 (1983).
Piper, J. M., Tonascia, J. & Matanoski, G. M. Heavy phenacetin use and bladder cancer in women aged 20 to 49 years. N. Engl. J. Med. 313, 292–295 (1985).
McLaughlin, J. K., Blot, W. J., Mehl, E. S. & Fraumeni, J. F. Jr. Relation of analgesic use to renal cancer: population-based findings. Natl Cancer Inst. Monogr. 69, 217–222 (1985).
Gago-Dominguez, M., Yuan, J. M., Castelao, J. E., Ross, R. K. & Yu, M. C. Regular use of analgesics is a risk factor for renal cell carcinoma. Br. J. Cancer 81, 542–548 (1999).
Tavani, A. & La Vecchia, C. Epidemiology of renal-cell carcinoma. J. Nephrol. 10, 93–106 (1997).
McLaughlin, J. K., Lipworth, L. & Tarone, R. E. Epidemiologic aspects of renal cell carcinoma. Semin. Oncol. 33, 527–533 (2006).
Rothwell, P. M. et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 377, 31–41 (2011).
Mahmud, S. M., Franco, E. L. & Aprikian, A. G. Use of nonsteroidal anti-inflammatory drugs and prostate cancer risk: a meta-analysis. Int. J. Cancer 127, 1680–1691 (2010).
Norrish, A. E., Jackson, R. T. & McRae, C. U. Non-steroidal anti-inflammatory drugs and prostate cancer progression. Int. J. Cancer 77, 511–515 (1998).
Neugut, A. I. et al. Association between coronary heart disease and cancers of the breast, prostate, and colon. Cancer Epidemiol. Biomarkers Prev. 7, 869–873 (1998).
Irani, J. et al. Effect of nonsteroidal anti-inflammatory agents and finasteride on prostate cancer risk. J. Urol. 168, 1985–1988 (2002).
Menezes, R. J., Swede, H., Mettlin, C. & Moysich, K. B. Regular aspirin use and risk of prostate cancer. In Proceedings of the American Association for Cancer Research Annual Meeting. 43, 933 (San Francisco, 2002).
Menezes, R. J., Swede, H., Niles, R. & Moysich, K. B. Regular use of aspirin and prostate cancer risk (United States). Cancer Causes Control 17, 251–256 (2006).
Bosetti, C. et al. Aspirin and the risk of prostate cancer. Eur. J. Cancer Prev. 15, 43–45 (2006).
Liu, X., Plummer, S. J., Nock, N. L., Casey, G. & Witte, J. S. Nonsteroidal antiinflammatory drugs and decreased risk of advanced prostate cancer: modification by lymphotoxin alpha. Am. J. Epidemiol. 164, 984–989 (2006).
Mahmud, S. M., Tanguay, S., Begin, L. R., Franco, E. L. & Aprikian, A. G. Non-steroidal anti-inflammatory drug use and prostate cancer in a high-risk population. Eur. J. Cancer Prev. 15, 158–164 (2006).
Harris, R. E., Beebe-Donk, J. & Alshafie, G. A. in Inflammation in the Pathogenesis of Chronic Diseases (ed. Harris, R. E.) 193–212 (Springer, New York, 2007).
Salinas, C. A. et al. Use of aspirin and other nonsteroidal antiinflammatory medications in relation to prostate cancer risk. Am. J. Epidemiol. 172, 578–590 (2010).
DerSimonian, R. & Laird, N. Meta-analysis in clinical trials. Control Clin. Trials 7, 177–188 (1986).
Greenland, S. Quantitative methods in the review of epidemiologic literature. Epidemiol. Rev. 9, 1–30 (1987).
Paganini-Hill, A., Chao, A., Ross, R. K. & Henderson, B. E. Aspirin use and chronic diseases: a cohort study of the elderly. BMJ 299, 1247–1250 (1989).
Thun, M. J., Namboodiri, M. M., Calle, E. E., Flanders, W. D. & Heath, C. W. Jr. Aspirin use and risk of fatal cancer. Cancer Res. 53, 1322–1327 (1993).
Schreinemachers, D. M. & Everson, R. B. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 5, 138–146 (1994).
Leitzmann, M. F. et al. Aspirin use in relation to risk of prostate cancer. Cancer Epidemiol. Biomarkers Prev. 11, 1108–1111 (2002).
Habel, L. A., Zhao, W. & Stanford, J. L. Daily aspirin use and prostate cancer risk in a large, multiracial cohort in the US. Cancer Causes Control 13, 427–434 (2002).
Perron, L., Bairati, I., Moore, L. & Meyer, F. Dosage, duration and timing of nonsteroidal antiinflammatory drug use and risk of prostate cancer. Int. J. Cancer 106, 409–415 (2003).
Garcia Rodriguez, L. A. & Gonzalez-Perez, A. Inverse association between nonsteroidal anti-inflammatory drugs and prostate cancer. Cancer Epidemiol. Biomarkers Prev. 13, 649–653 (2004).
Ratnasinghe, L. D. et al. Aspirin use and mortality from cancer in a prospective cohort study. Anticancer Res. 24, 3177–3184 (2004).
Platz, E. A. et al. Nonsteroidal anti-inflammatory drugs and risk of prostate cancer in the Baltimore Longitudinal Study of Aging. Cancer Epidemiol. Biomarkers Prev. 14, 390–396 (2005).
Jacobs, E. J. et al. A large cohort study of aspirin and other nonsteroidal anti-inflammatory drugs and prostate cancer incidence. J. Natl Cancer Inst. 97, 975–980 (2005).
Dasgupta, K. et al. Association between nonsteroidal anti-inflammatory drugs and prostate cancer occurrence. Cancer J. 12, 130–135 (2006).
Jacobs, E. J. et al. A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J. Natl Cancer Inst. 99, 608–615 (2007).
Siemes, C. et al. Protective effect of NSAIDs on cancer and influence of COX-2 C(-765G) genotype. Curr. Cancer Drug Targets 8, 753–764 (2008).
Brasky, T. M. et al. Nonsteroidal anti-inflammatory drugs and prostate cancer risk in the VITamins And Lifestyle (VITAL) cohort. Cancer Epidemiol. Biomarkers Prev. 19, 3185–3188 (2010).
Dhillon, P. K., Kenfield, S. A., Stampfer, M. J. & Giovannucci, E. L. Long-term aspirin use and the risk of total, high-grade, regionally advanced and lethal prostate cancer in a prospective cohort of health professionals, 1988–2006. Int. J. Cancer 128, 2444–2452 (2011).
Murad, A. S. et al. Associations of aspirin, nonsteroidal anti-inflammatory drug and paracetamol use with PSA-detected prostate cancer: findings from a large, population-based, case-control study (the ProtecT study). Int. J. Cancer 128, 1442–1448 (2011).
Mahmud, S. M. et al. Use of non-steroidal anti-inflammatory drugs and prostate cancer risk: a population-based nested case-control study. PLoS ONE 6, e16412 (2011).
Genkinger, J. M., De Vivo, I., Stampfer, M. J., Giovannucci, E. & Michaud, D. S. Nonsteroidal antiinflammatory drug use and risk of bladder cancer in the health professionals follow-up study. Int. J. Cancer 120, 2221–2225 (2007).
Daugherty, S. E. et al. Nonsteroidal antiinflammatory drugs and bladder cancer: a pooled analysis. Am. J. Epidemiol. 173, 721–730 (2011).
McCredie, M., Ford, J. M. & Stewart, J. H. Risk factors for cancer of the renal parenchyma. Int. J. Cancer 42, 13–16 (1988).
Mellemgaard, A. et al. Risk factors for renal cell carcinoma in Denmark: role of medication and medical history. Int. J. Epidemiol. 23, 923–930 (1994).
McCredie, M. et al. International renal-cell cancer study. II. Analgesics. Int. J. Cancer 60, 345–349 (1995).
Bosetti, C. et al. Aspirin and the risk of prostate cancer. Eur. J. Cancer Prev. 15, 43–45 (2006).
Tavani, A. et al. Aspirin and risk of renal cell cancer in Italy. Eur. J. Cancer Prev. 19, 272–274 (2010).
Cho, E. et al. Prospective evaluation of analgesic use and risk of renal cell cancer. Arch. Intern. Med. 171, 1487–1493 (2011).
Acknowledgements
This work was conducted with the financial support of the Italian Association for Cancer Research. The authors thank Mrs I. Garimoldi for editorial assistance.
Author information
Authors and Affiliations
Contributions
C. Bosetti wrote the article and contributed to researching the article, discussion of content, and editing the manuscript before submission. V. Rosato contributed to researching the article and editing the manuscript before submission. S. Gallus and C. La Vecchia contributed to the discussion of content and editing the manuscript before submission.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Bosetti, C., Rosato, V., Gallus, S. et al. Aspirin and urologic cancer risk: an update. Nat Rev Urol 9, 102–110 (2012). https://doi.org/10.1038/nrurol.2011.219
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2011.219
This article is cited by
-
Chronic prednisone, metformin, and nonsteroidal anti-inflammatory drug use and clinical outcome in a cohort of bladder cancer patients undergoing radical cystectomy in Québec, Canada
BMC Urology (2023)
-
Anti-inflammatory use may not negatively impact oncologic outcomes following intravesical BCG for high-grade non-muscle-invasive bladder cancer
World Journal of Urology (2017)
-
Low-dose aspirin or other nonsteroidal anti-inflammatory drug use and prostate cancer risk: a nationwide study
Cancer Causes & Control (2016)
-
Aspirin use decreases the risk of prostate cancer recurrence after post-prostatectomy radiotherapy
Journal of Radiation Oncology (2015)
-
Prostate cancer risk and nonsteroidal antiinflammatory drug use in the Finnish prostate cancer screening trial
British Journal of Cancer (2014)